|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.14 CNY | +0.26% |
|
-0.98% | +0.46% |
| 27/25/27 | Tasly Pharmaceutical's Q3 Profit Rises 17%, Revenue Slips 3%; Shares Down 1% | MT |
| 24/25/24 | Tasly pharmaceutical group Q3 net profit up 16.6% Y/Y | RE |
| Capitalization | 2.26TCr 324.98Cr 276.98Cr 256.63Cr 241.36Cr 449.26Cr 30TCr 481.92Cr 2.96TCr 1.17TCr 14TCr 1.22TCr 1.19TCr 51TCr | P/E ratio 2025 * |
19x | P/E ratio 2026 * | 15.9x |
|---|---|---|---|---|---|
| Enterprise value | 1.97TCr 282.58Cr 240.84Cr 223.15Cr 209.87Cr 390.65Cr 26TCr 419.04Cr 2.58TCr 1.02TCr 12TCr 1.06TCr 1.04TCr 45TCr | EV / Sales 2025 * |
2.24x | EV / Sales 2026 * | 2.18x |
| Free-Float |
49.28% | Yield 2025 * |
4.72% | Yield 2026 * | 4.8% |
| 1 day | +0.26% | ||
| 1 week | -0.98% | ||
| Current month | +0.46% | ||
| 1 month | -0.59% | ||
| 3 months | -4.78% | ||
| 6 months | -6.54% | ||
| Current year | +0.46% |
| 1 week | 14.95 |  | 15.49 |
| 1 month | 14.95 | | 15.49 |
| Current year | 14.95 | | 15.49 |
| 1 year | 14.13 | | 17.69 |
| 3 years | 11.45 | | 18 |
| 5 years | 9.2 | | 18 |
| 10 years | 9.2 | | 34.22 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jin Yong Cai
CEO | Chief Executive Officer | 54 | 08/05/2024 |
Jie Wei
DFI | Director of Finance/CFO | 49 | 09/07/2018 |
Ying Zhao
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Xiao Meng Jiang
BRD | Director/Board Member | 62 | 17/08/2007 |
Ai Jian Wang
BRD | Director/Board Member | 72 | 02/06/2021 |
Jin Yong Cai
BRD | Director/Board Member | 54 | 25/03/2006 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.26% | -0.98% | +6.54% | +31.42% | 323.96Cr | |
| +0.22% | -3.57% | -15.75% | -32.80% | 616.07Cr | |
| -0.20% | -1.64% | -21.78% | +17.71% | 452.46Cr | |
| +0.35% | -2.15% | +51.95% | +44.08% | 438.75Cr | |
| -0.96% | -2.01% | +11.43% | -39.04% | 426.35Cr | |
| +1.59% | +3.11% | -4.48% | -7.78% | 350.23Cr | |
| +0.77% | +2.11% | +10.63% | -19.66% | 254.88Cr | |
| -0.33% | -0.69% | +16.43% | +4.23% | 199.78Cr | |
| +1.39% | -0.94% | -0.19% | +52.19% | 168.87Cr | |
| -0.41% | +2.47% | +13.10% | +61.85% | 168.84Cr | |
| Average | +0.27% | +0.25% | +6.79% | +11.22% | 340.02Cr | |
| Weighted average by Cap. | +0.21% | -0.06% | +4.95% | +3.84% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 876.7Cr 125.96Cr 107.36Cr 99Cr 94Cr 174.14Cr 11TCr 186.79Cr 1.15TCr 453.62Cr 5.45TCr 472.37Cr 462.68Cr 20TCr | 937.18Cr 134.65Cr 114.77Cr 106.33Cr 100.01Cr 186.15Cr 12TCr 199.68Cr 1.23TCr 484.91Cr 5.83TCr 504.95Cr 494.6Cr 21TCr |
| Net income | 119.55Cr 17Cr 15Cr 14Cr 13Cr 24Cr 1.56TCr 25Cr 156.58Cr 62Cr 743.36Cr 64Cr 63Cr 2.71TCr | 141.83Cr 20Cr 17Cr 16Cr 15Cr 28Cr 1.85TCr 30Cr 185.75Cr 73Cr 881.86Cr 76Cr 75Cr 3.22TCr |
| Net Debt | -295.1Cr -42Cr -36Cr -33Cr -31Cr -59Cr -3.86TCr -63Cr -386.5Cr -152.69Cr -1.83TCr -159Cr -155.74Cr -6.7TCr | -220.2Cr -32Cr -27Cr -25Cr -23Cr -44Cr -2.88TCr -47Cr -288.4Cr -113.94Cr -1.37TCr -118.64Cr -116.21Cr -5TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/26/20 | 15.14 ¥ | +0.26% | 70,32,640 |
| 19/26/19 | 15.10 ¥ | +0.33% | 62,18,493 |
| 16/26/16 | 15.05 ¥ | -1.31% | 1,29,61,870 |
| 15/26/15 | 15.25 ¥ | -0.46% | 79,80,045 |
| 14/26/14 | 15.32 ¥ | -0.26% | 1,80,69,160 |
End-of-day quote Shanghai S.E., January 20, 2026
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 600535 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition